Avosentan is a competitive antagonist of Endothelin-1 (ET-1) with a high selectivity for the ETA receptor. Avosentan may be a potential option in the treatment of glaucoma.
相关文献及参考
[2]. Konieczka K, Meyer P, Schoetzau A, Neutzner A, Mozaffarieh M, Flammer J.
[3]. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G; ASCEND Study Group.
[4]. Dieterle W, Hengelage T.
[5]. Effect of SPP 301, an Endothelin Antagonist, on Intraocular Pressure in Glaucomatous Monkey Eyes By Wang, Rong-Fang; Podos, Steven M.; Serle, Janet B.; Baltatu, Ovidiu C. From Current Eye Research (2011), 36(1), 41-46.
Absolute bioavailability and pharmacokinetics of avosentan in man.
Absolute bioavailability and pharmacokinetics of avosentan in man.
Antidiuretic effects of the endothelin receptor antagonist avosentan.
Antidiuretic effects of the endothelin receptor antagonist avosentan.
Curr Eye Res. 2011 Feb;36(2):118-24.
Curr Eye Res. 2011 Feb;36(2):118-24.
Dieterle, W. et al.: J. Clin. Pharmacol., 44, 59 (2004); Dieterle, W. et al.: Int. J. Clin. Pharmacol. Ther., 43, 178 (2005); Wan